[en] Identification of biomarkers is a major issue for enhancement of chemotherapies. The molecular characterization of tissues necessitates the identification of thousands of biomolecules each participating in physiopathological processes. MALDI in-source decay (ISD) fragmentation has already been proven to be effective for protein characterization. However, the difficulty to identify proteins from complex mixtures such as tissue sections can limit the applications of this technique. In this study, we evidenced that tubulin has an unusual fragmentation pathway in the MALDI source. This striking property allowed the detecting of several mouse brain tubulin isotypes simultaneously by simply using laser fragmentation. Tubulin isoforms are consistent markers of a bad prognosis of solid tumors and could be the target of targeted chemotherapies. Such a direct molecular printout of tubulin in tissues is a milestone that should be useful either at preclinical or clinical stage.
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Ait-Belkacem, Rima; Aix-Marseille Université, INSERM, UMR911 CRO2, 13385, Marseille, France
Calligaris, David ; Université de Liège - ULiège > Département de chimie (sciences) > GIGA-R : Laboratoire de spectrométrie de masse (L.S.M.)
Sellami, Lina; Aix-Marseille Université, INSERM, UMR911 CRO2, 13385, Marseille, France
Villard, Claude; Aix-Marseille Université, INSERM, UMR911 CRO2, 13385, Marseille, France
Granjeaud, Samuel; Aix-Marseille Université, INSERM, U1068, CRCM, 13009, Marseille, France
Schembri, Therese; Aix-Marseille Université, INSERM, UMR911 CRO2, 13385, Marseille, France
Berenguer, Caroline; Aix-Marseille Université, INSERM, UMR911 CRO2, 13385, Marseille, France
Ouafik, L'Houcine; Aix-Marseille Université, INSERM, UMR911 CRO2, 13385, Marseille, France
Figarella-Branger, Dominique; Aix-Marseille Université, INSERM, UMR911 CRO2, 13385, Marseille, France
Chinot, Olivier; Aix-Marseille Université, INSERM, UMR911 CRO2, 13385, Marseille, France
Lafitte, Daniel; Aix-Marseille Université, INSERM, UMR911 CRO2, 13385, Marseille, France
Language :
English
Title :
Tubulin isoforms identified in the brain by MALDI in-source decay
Verdier-Pinard P., Pasquier E., Xiao H., Burd B., Villard C., Lafitte D., et al. Tubulin proteomics: towards breaking the code. Anal Biochem 2009, 384(2):197-206.
Lu Q., Luduena R.F. Removal of beta III isotype enhances taxol induced microtubule assembly. Cell Struct Funct 1993, 18(3):173-182.
Ranganathan S., Dexter D.W., Benetatos C.A., Chapman A.E., Tew K.D., Hudes G.R. Increase of beta(III)- and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance. Cancer Res Jun 1 1996, 56(11):2584-2589.
Kavallaris M., Kuo D.Y., Burkhart C.A., Regl D.L., Norris M.D., Haber M., et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest Sep 1 1997, 100(5):1282-1293.
Ranganathan S., Benetatos C.A., Colarusso P.J., Dexter D.W., Hudes G.R. Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer Feb 1998, 77(4):562-566.
Kavallaris M., Burkhart C.A., Horwitz S.B. Antisense oligonucleotides to class III beta-tubulin sensitizes drug-resistant cells to Taxol. Br J Cancer Jun 1999, 80(7):1020-1025.
Banerjee A. Increased levels of tyrosinated alpha-, beta(III)-, and beta(IV)-tubulin isotypes in paclitaxel-resistant MCF-7 breast cancer cells. Biochem Biophys Res Commun Apr 26 2002, 293(1):598-601.
Mozzetti S., Ferlini C., Concolino P., Filippetti F., Raspaglio G., Prislei S., et al. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res Jan 1 2005, 11(1):298-305.
Gan P.P., McCarroll J.A., Byrne F.L., Garner J., Kavallaris M. Specific β-tubulin isotypes can functionally enhance or diminish epothilone B sensitivity in non-small cell lung cancer cells. PLoS One 2011, 6(6):e21717. [Epub 2011 Jun 29].
Bonnel D., Longuespee R., Franck J., Roudbaraki M., Gosset P., Day R., et al. Multivariate analyses for biomarkers hunting and validation through on-tissue bottom-up or in-source decay in MALDI-MSI: application to prostate cancer. Anal Bioanal Chem Jul 2011, 401(1):149-165.
Debois D., Bertrand V., Quinton L., De Pauw-Gillet M.C., De Pauw E. MALDI-in source decay applied to mass spectrometry imaging: a new tool for protein identification. Anal Chem 2010, 82(10):4036-4045.
Demeure K., Gabelica V., De Pauw E.A. New advances in the understanding of the in-source decay fragmentation of peptides in MALDI-TOF-MS. J Am Soc Mass Spectrom 2010, 21(11):1906-1917.
Gabelica V., Schulz E., Karas M. Internal energy build-up in matrix-assisted laser desorption/ionization. J Mass Spectrom 2004, 39(6):579-593.
Takayama M. Susceptible region of myoglobins to in-source decay using matrix-assisted laser desorption/ionization coupled with reflectron time-of-flight mass spectrometer. J Mass Spectrom Soc Jpn 2002, 50:304-310.
Takayama M. N-Ca bond cleavages of the peptide backbone via hydrogen abstraction. J Am Soc Mass Spectrom 2001, 12:1044-1049.
Sakakura M., Takayama M. In-source decay and fragmentation characteristics of peptides using 5-aminosalicylic acid as a matrix in matrix-assisted laser desorption/ionization mass spectrometry. J Am Soc Mass Spectrom Jun 2010, 21(6):979-988.
Demeure K., Quinton L., Gabelica V., De Pauw E. Rational selection of the optimum MALDI matrix for top-down proteomics by in-source decay. Anal Chem 2007, 79(22):8678-8685.
Sachon E., Clodic G., Blasco T., Jacquot Y., Bolbach G. In-source fragmentation of very labile peptides in matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Anal Chem 2009, 81(21):8986-8992.
Suckau D., Resemann A. T3-sequencing: targeted characterization of the N- and C-termini of undigested proteins by mass spectrometry. Anal Chem 2003, 75(21):5817-5824.
Kocher T., Engstrom A., Zubarev R.A. Fragmentation of peptides in MALDI in-source decay mediated by hydrogen radicals. Anal Chem 2005, 77(1):172-177.
Calligaris D., Villard C., Terras L., Braguer D., Verdier-Pinard P., Lafitte D. MALDI in-source decay of high mass protein isoforms: application to alpha- and beta-tubulin variants. Anal Chem 2010, 82(14):6176-6184.
Carabetta V.J., Li T., Shakya A., Greco T.M., Cristea I.M. Integrating Lys-N proteolysis and N-terminal guanidination for improved fragmentation and relative quantification of singly-charged ions. J Am Soc Mass Spectrom Jun 2010, 21(6):1050-1060.
Franck J., Longuespée R., Wisztorski M., Van Remoortere A., Van Zeijl R., Deelder A., et al. MALDI mass spectrometry imaging of proteins exceeding 30,000daltons. Med Sci Monit Sep 2010, 16(9):BR293-BR299.
Taban I.M., Altelaar A.F., van der Burgt Y.E., McDonnell L.A., Heeren R.M., Fuchser J., et al. Imaging of peptides in the rat brain using MALDI-FTICR mass spectrometry. J Am Soc Mass Spectrom 2007, 18(1):145-151.
Lagarrigue M., Becker M., Lavigne R., Deininger S.O., Walch A., Aubry F., et al. Revisiting rat spermatogenesis with MALDI imaging at 20-microm resolution. Mol Cell Proteomics 2011, 10(3). [M110 005991].
Katsetos C.D., Del Valle L., Geddes J.F., Assimakopoulou M., Legido A., Boyd J.C., et al. Aberrant localization of the neuronal class III beta-tubulin in astrocytomas. Arch Pathol Lab Med 2001, 125(5):613-624.
Katsetos C.D., Del Valle L., Geddes J.F., Aldape K., Boyd J.C., Legido A., et al. Localization of the neuronal class III beta-tubulin in oligodendrogliomas: comparison with Ki-67 proliferative index and 1p/19q status. J Neuropathol Exp Neurol 2002, 61(4):307-320.
Katsetos C.D., Draberova E., Smejkalova B., Reddy G., Bertrand L., de Chadarevian J.P., et al. Class III beta-tubulin and gamma-tubulin are co-expressed and form complexes in human glioblastoma cells. Neurochem Res 2007, 32(8):1387-1398.
